报销
医学
药品审批
医疗保健
肿瘤科
内科学
重症监护医学
家庭医学
医学物理学
药理学
药品
经济增长
经济
作者
Ataru Igarashi,Shiro Tanaka,Raf De Moor,Nan Li,Mariko Hirozane,David Bin-Chia Wu,Li Wen Hong,Dae Young Yu,Mahmoud Hashim,Brian Hutton,Krista Tantakoun,Christopher Olsen,Fatemeh Mirzayeh Fashami,Imtiaz A. Samjoo,Chris Cameron
标识
DOI:10.1007/s12325-024-03013-6
摘要
Indirect treatment comparisons (ITCs) evaluate novel treatments compared to appropriate comparators when direct evidence is unavailable or infeasible. The objective of this study was to highlight the prevalence of different ITC methods in oncology drug submissions and to provide insights into how ITCs have been used in recent regulatory approval, reimbursement recommendations, or pricing decisions across various regions and diverse assessment frameworks.
科研通智能强力驱动
Strongly Powered by AbleSci AI